上皮性卵巢癌患者ERCC1 N118N基因型与铂类药物化疗敏感性关系的研究  

Association of ERCC1 N118N gene polymorphism with chemotherapy sensitivity in ovarian cancer patients with platinum-based chemotherapy

作　　者：夏婷[1] 朱笕青[1] 郑智国[2] 杨悦[1] 

机构地区：[1]浙江省肿瘤医院妇科,杭州310022 [2]浙江省肿瘤医院肿瘤研究所,杭州310022

出　　处：《浙江医学》2015年第9期741-742,755,共3页Zhejiang Medical Journal

基　　金：浙江省自然科学基金资助项目(Y2100593)

摘　　要：目的探讨不同核苷酸切除修复交叉互补基因组1(ERCC1)N1侣N基因型与接受铂类药物化疗的上皮性卵巢癌患者化疗敏感性的关系。方法采用Taqrnan探针基因分型技术检测92例上皮性卵巢癌患者外周血EFtCC1 N1 18N单核苷酸多态性。所有患者均接受以铂类药物为主的方案化疗(紫杉醇+顺铂或环磷酰胺+顺铂),比较不同基因型与患者化疗敏感性的关系。结果92例患者中第1 18位密码子基因型的分布是CT+TT型为42.4%,CC型57.6%;CT+TT型者对铂类化疗药物的敏感性显著高于CC型者(P=0.029)。结论 ERCC1第118位密码子的基因多态性与卵巢癌患者铂类药物化疗敏感性有关。Objective To investigate the association of ERCC1 N118 N gene polymorphism with chemotherapy sensitivity in epithelial ovarian cancer patients treated with platinum- based chemotherapy （taxol＋ cisplatin, cyclophosphamide＋cisplatin）. Methods Ninety two patients with epithelial ovarian cancer treated with platinum- based chemotherapy were includ-ed in the study. Pre- treatment anticoagulated blood samples were col ected for extraction of genomic DNA. The TaqMan method was used to genotype single nucleotide polymorphisms （SNPs） in ERCC1 N118N gene. Results The genotype distribution at codon 118 was 57.6% with C/C and 42.4% with C/T＋TT. Platinum- resistance was less frequently in patients with the C/T ＋ T/T genotype （P=0.029）. Conclusion ERCC1 N118 N gene polymorphism may be associated with chemotherapy sensitivity in epithelial ovarian cancer patients treated with platinum- based chemotherapy.

关 键 词：卵巢癌 核苷酸切除修复交叉互补基因1 基因多态性 药物敏感性 

分 类 号：R737.31[医药卫生—肿瘤]